Kongtawelert P, Francis D J, Brooks P M, Ghosh P
Raymond Purves Research Laboratories, University of Sydney, St. Leonards, N.S.W., Australia.
Rheumatol Int. 1989;9(2):77-83. doi: 10.1007/BF00270249.
The effects of the chondroprotective agents (Arteparon, SP-54 and DH40J) on the release of proteoglycan degradation products (as keratan sulphate peptide fragments) from articular cartilage implanted into rat subcutaneous air pouches have been investigated by using an enzyme-linked immunosorbent-inhibition assay (ELISIA). The ELISIA technique was capable of quantitating the keratan sulphate peptides (KS peptides) in fluids within the range of 100-2,000 ng/ml by using the monoclonal antibody line 1/20/5-D-4 and human articular cartilage KS peptides as standard reagents. It was found that the levels of KS peptides present in the air-pouch fluid of rats treated with the chondroprotective drugs was significantly less than in fluid aspirated from the pouches of non-drug-treated control animals. On the basis of these findings we suggest that the assessment of KS peptide by ELISIAs may provide a useful means of monitoring proteoglycan breakdown products in biological fluids (e.g. synovial fluids or blood) and for evaluating the effects that antiarthritic drugs may have on this process.
通过酶联免疫吸附抑制测定法（ELISA），研究了软骨保护剂（阿特帕龙、SP - 54和DH40J）对植入大鼠皮下气囊的关节软骨中蛋白聚糖降解产物（作为硫酸角质素肽片段）释放的影响。ELISA技术能够使用单克隆抗体1/20/5 - D - 4和人关节软骨硫酸角质素肽作为标准试剂，在100 - 2000 ng/ml范围内对液体中的硫酸角质素肽（KS肽）进行定量。结果发现，用软骨保护药物治疗的大鼠气囊液中KS肽的水平显著低于未用药治疗的对照动物气囊抽出液中的水平。基于这些发现，我们认为通过ELISA评估KS肽可能为监测生物体液（如滑液或血液）中的蛋白聚糖分解产物以及评估抗关节炎药物对该过程可能产生的影响提供一种有用的方法。
